Women's Health References

1. Womens Health Initiative Investigators. Risks and benefits ofestrogen plus progestin in healthy postmenopausal women. JAMA. 288(3):321-33,2002. www.jama.com.

2. Kam IW et al. Dietary supplement use among menopausal women attending aSan Francisco health conference. Menopause. 9(1):72-8, 2002. www.menopausejournal.com.

3. Ariyo AA, Villablanca AC. Estrogens and lipids.Can HRT designer estrogens, and phytoestrogens reduce cardiovascular riskmarkers after menopause? Postgrad Med. 111(1):23-30, 2002. www.postgradmed.com.

4. Dewell A et al. The effects of soy-derivedphytoestrogens on serum lipids and lipoproteins in moderatelyhypercholesterolemic postmenopausal women. J Clin Endocrinol Metab.87(1):118-21, 2002. http://jcem.endojournals.org.

5. Vigna GB et al. Plasma lipoproteins insoy-treated postmenopausal women: a double blind, placebo-controlled trial.Nutr Metab Cardiovasc Dis. 10(6):315-22, 2000. www.medikal.it/index_en.htm.

6. Arena S et al. A natural alternative to menopausal hormone replacementtherapy. Phytoestrogens. Minerva Ginecol. 54(1):53-7, 2002.

7. Greendale GA et al. Dietary soy isoflavones andbone mineral density: results from the Study of Womens Health Across theNation. Am J Epidemiol. 155(8):746-54, 2002. www.aje.oupjournals.org.

8. Scambia G et al. Clinical effects of astandardized soy extract in postmenopausal women: a pilot study. Menopause.7(2):105-11. www.menopausejournal.com.

9. Upmalis DH et al. Vasomotor symptom relief by soyisoflavone extract tablets in postmenopausal women: a multicenter, double-blind,randomized, placebo-controlled study. Menopause. 7(4):236-42, 2000. www.menopausejournal.com.

10. Albertazzi P et al. The effect of dietary soy supplementation on hotflashes. Obstet Gynecol. 91:6-11, 1998. www.greenjournal.org.

11. Ju YH et al. Dietary genistein negates the inhibitory effect ofTamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cellsimplanted in athymic mice. Cancer Res. 62(9):2474-77, 2002. http://cancerres.aacrjournals.org.

12. Wu AH et al. Soy intake and other lifestyle determinants of serumestrogen levels among postmenopausal Chinese women in Singapore. CancerEpidemiol Biomarkers Prev. 11(9):844-51, 2001. http://cebp.aacrjournals.org.

13. Alexandersen P et al. Ipriflavone in the treatment of postmenopausalosteoporosis: a randomized controlled trial. JAMA. 285(11):1482-8, 2001. www.jama.com.

14. Tsunoda N et al. Absorption in Humans of Isoflavones from Soy and RedClover Is Similar. J Nutr. 132(8):2199-201, 2002. www.nutrition.org.

15. van de Weijer P, Barentsen R. Isoflavones from red clover (Promensil(R))significantly reduce menopausal hot flush symptoms compared with placebo.Maturitas. 42(3):187, 2002.

16. Lucas EA et al. Flaxseed improves lipid profile without alteringbiomarkers of bone metabolism in postmenopausal women. J Clin EndocrinolMetab. 87(4):1527-32, 2002. http://jcem.endojournals.org.

17. Bagchi D et al. Benefits of resveratrol in womens health. DrugsExp Clin Res. 27(5-6):233-48, 2001.

18. Bagchi D et al. Phytoestrogen, resveratrol and womens health.Res Comm Pharmacol Toxicol. 5(1-2):107-21, 2000.

19. Liske E et al. Physiological investigation of a unique extract ofblack cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical studydemonstrates no systemic estrogenic effect. J Womens Health Gen Based Med.11(2):163-74, 2002. www.liebertpub.com/JWH/default1.asp.

20. Stevinson D, Ernst E. Valerian for insomnia: asystematic review of randomized clinical trials. Sleep Med. 1(2):91-99, 2000.www.elsevier.com/locate/sleep.

21. Donath F et al. Critical evaluation of theeffect of valerian extract on sleep structure and sleep quality.Pharmacophychiatry. 33(2):47-53, 2000. www.thieme.de/pharmaco.

22. Sartippour MR et al. Green tea inhibits vascularendothelial growth factor (VEGF) induction in human breast cancer cells. JNutr. 132:2307-11, 2002. www.nutrition.org.

23. Ching S et al. Serum levels of micronutrients, antioxidants and totalantioxidant status predict risk of breast cancer in a case control study. JNutr. 132:303-6, 2002. www.nutrition.org.

24. Schwenke DC. Does lack of tocopherols and tocotrienols put women atincreased risk of breast cancer? J Nutr Biochem. 13(1):2-20, 2002. www.elsevier.com/locate/jnutbio.

25. Fleischauer AT et al. Dietary antioxidants, supplements and risk ofepithelial ovarian cancer. Nutr Cancer. 40(2):92-8, 2002. www.erlbaum.com/Journals/journals/NC/nc.htm.

26. Huncharek M et al. Dietary beta-carotene intake and the risk ofepithelial ovarian cancer: a meta-analysis of 3,782 subjects from fiveobservational studies. In Vivo. 15(4):339-43, 2001. www.iiar-anticancer.org/index2.htm.

27. Cramer DW et al. Carotenoids, antioxidants and ovarian cancer risk inpre- and post-menopausal women. Int J Cancer. 94(1):128-34, 2001.www3.interscience.wiley.com.

28. Civitelli R et al. Alveolar and postcranial bone density inpostmenopausal women receiving hormone/estrogen replacement therapy. Arch IntMed. 162(12):1409-15, 2002. http://archinte.ama-assn.org.

29. Dawson-Hughes B. Calcium Supplementation and Bone Loss: A Review ofControlled Clinical Trials. Am J Clin Nutr. 54(1):274S-80S, 1991. www.ajcn.org.

30. Sakhaee K et al. Meta-analysis of calcium bioavailability: acomparison of calcium citrate with calcium carbonate. Am J Ther. 6(6):313-21,1999. www.americantherapeutics.com.

31. Reid IR et al. Effects of calcium supplementation on serum lipidconcentrations in normal older women: a randomized controlled trial. Am JMed. 112(5):343-7, 2002. www-east.elsevier.com/ajm/menu.html.

32. Jensen C et al. Long-term effects of nutrient intervention on markersof bone remodeling and calciotropic hormones in late-postmenopausal women. AmJ Clin Nutr. 75(6):1114-20, 2002. www.ajcn.org.

33. Twiss JJ et al. Bone mineral density in postmenopausal breast cancersurvivors. J Am Acad Nurse Pract. 13(6):276-84, 2001. www.slackinc.com/allied/np/nphome.htm.

34. Rassouli A et al. Determination of serum 25-hydroxyvitamin D(3) levelsin early postmenopausal Iranian women: relationship with bone mineral density.Bone. 29(5):428-30, 2001. www.elsevier.com/locate/boneonline.

35. Mezquita-Raya P et al. Relation between vitamin D insufficiency, bonedensity, and bone metabolism in healthy postmenopausal women. J Bone MinerRes. 16(8):1408-15, 2001. www.jbmr-online.org.

36. Brot C et al. Vitamin D status and its adequacy in healthy Danishperimenopausal women: relationships to dietary intake, sun exposure and serumparathyroid hormone. Br J Nutr. 86(Suppl 1):S97-103, 2001. www.cabi-publishing.org/journals/bjn.

37. Mezquita-Raya P et al. Prevalence of vitamin D deficiency inpopulations at risk for osteoporosis: impact on bone integrity. Med Clin (Barc).119(3):85-9, 2002.

38. Shin MH et al. Intake of dairy products, calcium and vitamin D andrisk of breast cancer. JNCI. 94(17):1301-10, 2002. http://jncicancerspectrum.oupjournals.org/jnci.

39. Grant WB. An ecologic study of dietary and solar ultraviolet-B linksto breast carcinoma mortality rates. Cancer. 94(1):272-81, 2002. www.interscience.wiley.com/jpages/0008-543X.

40. Bendich A "Micronutrients in women's health and immunefunction." Nutrition. 17(10):858-67, 2001. www.elsevier.com/locate/nut

41. Christian P "Maternal nutrition, health and survival." NutrRev. 60(5pt). 2:S59-63, 2002. www.ilsi.org/publications/reviews.html.

42. Olshan AF et al. Maternal Vitamin Use and Reduced Risk ofNeuroblastoma. Epidemiology. 13(5):575-80, 2002. www.epidem.com.

43. Iqbal MM. Birth defects: prevention of neural tube defects bypericonceptional use of folic acid and screening. J Prev Soc Med.18(1):52-65, 1999.

44. Thompson JR et al. "Maternal folate supplementation in pregnancy andprotection against acute lymphoblastic leukemia in childhood: a case controlstudy." Lancet. 358:1935-40, 2001. www.thelancet.com

45. Botto LD et al. "Occurrence of omphalocele in relation to maternalmultivitamin use." Pediatrics. 109(5):904-8, 2002. www.pediatrics.org.

46. Montoya DA et al. "Prenatal choline exposure alters hippocampalresponsiveness to cholinergenic stimulation in adulthood." Brain Res DevBrain Res. 123(1):25-32, 2000. www.sciencedirect.com/science/journal/01653806.

47. Guo-Ross SX et al. "Prenatal choline supplementation protectsagainst postnatal neurotoxicity." J Neurosci. 22(1):RC195, 2002. www.jneurosci.org.

48. Mock DM et al. Marginal biotin deficiency during normal pregnancy.Am J Clin Nutr. 75(2):295-99, 2002. www.ajcn.org.

49. Johnson LE, DeLuca HF. Reproductive defects are corrected in vitaminD-deficient female rats fed a high calcium, phosphorus and lactose diet. JNutr. 132:2270-3, 2002. www.nutrition.org.

50. Zhang C et al. Vitamin C and the risk of preeclampsia--results fromdietary questionnaire and plasma assay. Epidemiology. 13(4):409-16, 2002. www.epidem.com.

51. Crowther CA et al. "Calcium supplementation in nulliparous women forthe prevention of pregnancy-induced hypertension, preeclampsia and pretermbirth." Aust NZ Obstet Gynecol, 39, 1:12-8, 1999.

52. Belizan JM et al. "Calcium supplementation to prevent hypertensivedisorders of pregnancy." NEJM, 325, 20:1399-405, 1991. http://content.nejm.org.

53. Bodnar LM et al. High prevalence of postpartum anemia among low-incomewomen in the United States. Am J Obstet Gynecol. 185(2):438-43, 2001. www.mosby.com/Mosby/Periodicals/Medical/AJOG/ob.html.

54. Szarfarc SC et al. "Relative effectiveness of iron bis-glycinatechelate and ferrous sulfate in the control of iron deficiency in pregnantwomen." Archivos Latinoamericans de Nutricion. S51(1):42-7, 2001.

55. Liguori L. Iron protein succinylate in the treatment of irondeficiency: controlled, double-blind, multicenter clinical trial on over 1,000patients. In J Clin Pharmacol Ther Toxicol. 31(3):103-23, 1993.

56. Chung CS et al. A single 60-mg iron dose decreases zinc absorption inlactating women. J Nutr. 132(7):1903-5, 2002. www.nutrition.org.

57. Luna C, Villanueva LA "Physiological significance of zinc: perinatalapproximation." Gynecol Obstet Mex. 2(69):77-81, 2001.

58. Magpie Trial Collaborative Group "Do women with pre-eclampsia andtheir babies benefit from magnesium sulphate?" Lancet. 359:1877-90, 2002. www.thelancet.com.

59. Williams MA et al. "Omega-3 fatty acids in maternal erythrocytes andrisk of preeclampsia." Epidemiology. 6(3):232-7, 1995. www.epidem.com.

60. Cheruku SR et al. Higher maternal plasma docosahexaenoic acid duringpregnancy is associated with more mature neonatal sleep-state patterning. AmJ Clin Nutr. 76(3):608-13, 2002. www.ajcn.org.

61. Uauy R et al. "Essential fatty acids in visual and braindevelopment." Lipids. 36(9):885-95, 2001. www.aocs.org.

62. Holman RT, Johnson SB & Ogburn PL "Deficiency of essential fattyacids and membrane fluidity during pregnancy and lactation." Proc Natl AcadSci USA. 88:4835-9, 1991. www.pnas.org.

63. Hibbeln JR. Seafood consumption, the DHA content of mothers milkand prevalence rates of postpartum depression: a cross-national, ecologicalanalysis. J Affect Disord. 69(1-3):15-29, 2002. www.elsevier.nl/locate/jad.

64. Ziaei S et al. A randomized, placebo-controlled trial to determine theeffect of vitamin E in treatment of primary dysmenorrhoea. BJOG.108(11):1181-3, 2001. www.womenshealth-elsevier.com/doc/journals/bjog1.html.

65. Rohdewald P et al. The treatment of gynaecologial disorders withPycnogenol(R)). European Bull Drug Res. 7(2):30-32, 1999.www.europharma2000.it/Servizio%201.htm.

66. Schellenberg R. Treatment for the premenstrual syndrome with Agnuscastus fruit extract: prospective, randomized, placebo controlled study. BMJ.322:134-137, 2001. http://bmj.com.

67. Ingram DM et al. "A double-blind randomized controlled trial ofisoflavones in the treatment of cyclical mastalgia." Breast. 11(2):170-174,2002. http://www.harcourt-international.com/journals/brst.

68. Thys-Jacobs S. Micronutrients and the premenstrual syndrome: the casefor calcium. J Am Coll Nutr. 19(2):220-7, 2000. www.am-coll-nutr.org/jacn/jacn.htm.

69. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrualsyndrome. J Clin Psychiatry. 61(Suppl 12):22-7, 2000. www.psychiatrist.com.